INS and metabolic syndrome: Given that specific bacterial taxa have been associated with insulin sensitivity, inflammation, and lipid metabolism, microbiota-targeted therapies, including faecal microbiota transplantation, next-generation probiotics, and microbiome-modulating drugs, could revolutionize MetS management.